Cellular and secretome profiling uncover immunological biomarkers in the prognosis of renal cell carcinoma patients

Oncoimmunology. 2025 Dec;14(1):2481109. doi: 10.1080/2162402X.2025.2481109. Epub 2025 Mar 24.

Abstract

Renal cell carcinoma (RCC) is recognized as an immunogenic tumor, yet tumor-infiltrating lymphocytes often exhibit diminished effector function. However, the mechanisms underlying reduced T and NK cell activity in RCC remain unclear. Here, we examined the immune contexture in RCC patients undergoing nephrectomy to identify immune-related biomarkers associated with disease progression. Immune cell phenotypes and secretion profiles were assessed using flow cytometry and Luminex multiplex analysis. Supervised multivariate analysis revealed several changes of which frequencies of T and NK cells expressing CCR5, CXCR3, and PD-1 were elevated within tumors compared with peripheral blood. In addition, higher levels of regulatory T cells, PD-1+, and CXCR3+ T and NK cells were observed in patients with relapse following nephrectomy. With regards to soluble factors, tumor-derived CXCL8 was associated with higher Fuhrman grade and increased frequency of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). These biomarkers demonstrate potential relevance in the progression of RCC and merit further investigation in prospective studies.

Keywords: Biomarkers; CXCL8; NK cells; PD-1; T cells; prognosis; renal cell carcinoma.

MeSH terms

  • Aged
  • Biomarkers, Tumor* / immunology
  • Biomarkers, Tumor* / metabolism
  • Carcinoma, Renal Cell* / immunology
  • Carcinoma, Renal Cell* / metabolism
  • Carcinoma, Renal Cell* / pathology
  • Carcinoma, Renal Cell* / surgery
  • Female
  • Humans
  • Kidney Neoplasms* / immunology
  • Kidney Neoplasms* / metabolism
  • Kidney Neoplasms* / pathology
  • Kidney Neoplasms* / surgery
  • Killer Cells, Natural / immunology
  • Killer Cells, Natural / metabolism
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Male
  • Middle Aged
  • Myeloid-Derived Suppressor Cells / immunology
  • Nephrectomy
  • Prognosis

Substances

  • Biomarkers, Tumor

Grants and funding

This work was supported by The Swedish Cancer Society [#CAN21 1524 Pj and #CAN24 3655 Pj], The Cancer Research Funds of Radiumhemmet [#211253 and #241293], The Swedish Society for Medical Research [P17-0134], The Swedish Society of Medicine [SLS-960960], Region Stockholm [FoUI-974888 and FoUI-987561], Clas Groschinsky Foundation, Stiftelsen Tornspiran, Karolinska Institutet [#2024-03034], National Medical Research Council [OFIRG24jan-0111], and The Robert Lundberg Memorial Foundation [#2023-01810].